ArticleFrontiers in pharmacology2022
Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease.
Yuting Ma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
19 papers cite it
this papercites it